AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – What’s Next?

AIM ImmunoTech Inc. (NYSE:AIM) shares were down 8.1% on Monday . The stock traded as low as $0.18 and last traded at $0.19. Approximately 1,000,809 shares were traded during trading, an increase of 26% from the average daily volume of 791,607 shares. The stock had previously closed at $0.20.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AIM shares. Ascendiant Capital Markets reduced their price target on shares of AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating for the company in a research report on Tuesday, December 10th. Maxim Group reduced their price target on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, October 22nd.

AIM ImmunoTech Stock Down 8.1 %

The company has a market cap of $11.84 million, a P/E ratio of -0.39 and a beta of -0.36. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The company’s 50-day moving average is $0.21 and its two-hundred day moving average is $0.26.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).